MediPharm Labs Positioned to Serve Growing U.S. Pharmaceutical and Clinical Research Demand Following Cannabis Rescheduling

U.S. Reschedules Cannabis to Schedule III, Opening Research Avenues

MediPharm Labs Corp. welcomes the U.S. Department of Justice and DEA's final order rescheduling FDA-approved cannabis drug products and state-licensed medical cannabis from Schedule I to Schedule III of the Controlled Substances Act, effective April 22, 2026. This significant regulatory change is anticipated to materially reduce barriers to U.S. clinical research and pharmaceutical development. MediPharm Labs is strategically positioned to benefit, leveraging its FDA site registration, Health Canada Drug Establishment License, and extensive experience, including supplying product for over 10 active clinical trials since 2023. The company has a proven track record of shipping pharmaceutical-grade cannabis to the U.S. under previous Schedule I conditions and aims to support expanded U.S. research and pharmaceutical development, aligning with its manufacturing strategy for FDA-approved cannabis drug products.

• The U.S. government's reclassification of cannabis from Schedule I to Schedule III, effective April 22, 2026, marks a pivotal moment for medical cannabis research and development. This final order by the U.S. Department of Justice and DEA acknowledges the medical utility of cannabis, significantly easing regulatory hurdles that previously constrained clinical trials. The change is expected to accelerate U.S. research by facilitating access to standardized medical-grade cannabis from registered suppliers, thereby creating a clearer regulatory pathway for FDA-approved cannabis drug products and aligning with pharmaceutical manufacturing strategies.
• MediPharm Labs is exceptionally well-prepared to capitalize on the new regulatory environment. The company has a robust track record, having successfully shipped pharmaceutical-grade cannabis products into the United States multiple times since 2023, even under the stringent Schedule I classification. Its credentials include a GMP US FDA site registration and a Health Canada Drug Establishment License. Furthermore, MediPharm Labs has supplied materials for over 10 active clinical trials, including a U.S. National Institutes of Health-funded Phase 2 study, demonstrating its proven capability to support expanded U.S. clinical research and pharmaceutical development.
• The reclassification of cannabis to Schedule III is poised to unlock new investment opportunities and market growth. Institutional investors, previously deterred by "Schedule I trafficking" clauses, may now consider research-oriented cannabis companies, potentially increasing interest in firms like MediPharm Labs. This regulatory evolution could also encourage pharmaceutical companies that previously avoided cannabis due to its higher-risk classification to invest in research. Such renewed interest is expected to expand the pipeline of U.S. researchers and pharmaceutical companies seeking compliant active pharmaceutical ingredient (API) and clinical trial supply partners.

Rescheduling Unlocks Broader Cannabis Research Indications

Cannabis research has expanded far beyond substance use disorders, with clinical trials now investigating therapeutic applications across multiple medical conditions. Pain management represents the most extensively studied indication, while various intervention models are being tested to optimize therapeutic outcomes.

• Pain conditions emerge as the primary focus, including chronic musculoskeletal pain, neuropathic pain, arthritic pain, and chronic non-cancer pain, with pain being the primary reason for medical cannabis authorization in 76-77% of patients in Canadian studies

• Mental health disorders are increasingly studied, encompassing anxiety (reported in 32.9-38.7% of patients), depression, PTSD, psychotic disorders, and prodromal psychotic symptoms, with PTSD showing significant improvements after 6 weeks of treatment

• Neurological conditions demonstrate promising results, particularly multiple sclerosis-related spasticity, seizure disorders, and sleep disturbances including insomnia, with these outcomes classified as having "Positive or Potentially Positive" effects in high-quality systematic reviews

• Inflammatory bowel disease, specifically Crohn's disease, shows clinical promise with 90% of patients achieving clinical response (CDAI score decrease >100) versus 40% in placebo groups in controlled trials

• Rheumatological and musculoskeletal disorders, including arthritis and fibromyalgia, are being investigated for pain management and functional improvement, with preclinical studies suggesting benefits for osteoarthritis and osteoporosis

• Pharmacological intervention models include standardized cannabis products from licensed producers, specific THC/CBD ratios (such as 6.3% THC with 8% CBD), combination therapies with opioids, and isolated cannabinoid compounds like dronabinol and nabilone

• Study designs encompass randomized controlled trials within real-world healthcare systems, prospective registry studies extending up to 4 years, open-label studies, and network meta-analyses, with follow-up periods ranging from 6 weeks to 12 months

• Psychological intervention models integrate brief behavioral treatments, cognitive-behavioral therapy with motivational enhancement, contingency management protocols, and dialectical behavioral/acceptance and commitment therapies, often combined with pharmacological approaches

Unpacking Cannabis's Mechanisms of Action in Trials

Cannabis mechanisms are being investigated across a diverse range of medical conditions beyond substance use disorders, with research spanning autoimmune diseases, neuropsychiatric conditions, and pain management. The evidence base varies significantly across indications, from FDA-approved applications to early-stage preclinical research. Most clinical investigations utilize randomized controlled trial designs, though intervention models differ substantially based on the target condition.

• Autoimmune and inflammatory conditions including multiple sclerosis, rheumatoid arthritis, systemic lupus erythematosus, and type 1 diabetes mellitus are being studied using cannabinoids that modulate CB1, CB2, TRPV1, PPAR-α, and PPAR-γ receptors to downregulate immune responses and reduce proinflammatory cytokine production

• Neuropsychiatric disorders encompass seizure disorders (with FDA-approved CBD), schizophrenia, dementia-related neuropsychiatric symptoms, Alzheimer's disease agitation, anxiety, PTSD, and mood disorders, primarily investigated through randomized controlled trials with considerable variability in study design

• Pain management applications represent the most common indication, including chronic non-cancer pain, neuropathic pain, chemotherapy-induced symptoms, and acute pain conditions, typically evaluated in parallel-group randomized placebo-controlled trials

• Cancer-related symptoms including cachexia, appetite stimulation, and chemotherapy-induced nausea and vomiting are supported by FDA-approved cannabinoids (dronabinol and nabilone) and ongoing research with both synthetic and plant-derived compounds

• Intervention models predominantly utilize randomized controlled trial designs, with crossover studies noted specifically in Alzheimer's research (though not recommended for future trials), and factorial or sequential designs rarely employed across the cannabis research landscape

Optimizing Cannabis Clinical Trial Design with Biomarkers

Recent cannabis clinical trials have employed various biomarker and patient selection approaches, though standardized strategies remain limited. The studies reviewed demonstrate diverse methodologies for participant recruitment and biological assessment, while highlighting significant gaps in standardized measurement approaches.

• Inflammatory biomarker profiles in HIV populations - Studies measured 13 plasma biomarkers in people with HIV on antiretroviral therapy, finding cannabis use associated with higher soluble CD14 levels (β = 0.35; 95% CI: 0.09, 0.61) and former use linked to lower C-reactive protein levels

• Neurotrophic factor assessments - Brain-derived neurotrophic factor (BDNF) expression and mature BDNF/precursor BDNF ratios were correlated with cognitive outcomes in people with HIV who used cannabis, alongside metabolic shifts in monocyte-derived macrophages

• Symptom-based patient selection criteria - Trials recruited participants with moderate-to-severe cannabis use disorder (mean symptoms 9.27 ± 1.10), risky cannabis use defined by ASSIST scores ≥4, or specific medical conditions including anxiety, depression, pain, and insomnia

• Cognitive and psychosocial assessments - First-episode psychosis studies examined cognitive predictors including processing speed, social cognition, and negative symptoms in relation to cannabis use patterns, frequency, and dosing

• Standardized use pattern documentation - Studies assessed cannabis use characteristics through structured interviews capturing disorder status, recency, frequency, dose, and days of use in the previous 30 days, though researchers noted significant limitations in standardized measurement approaches

Assessing Cannabis's Safety and Tolerability Across Indications

Published safety and tolerability data for cannabis across medical indications reveals a complex profile with generally manageable adverse events but important considerations for specific populations. The most recent comprehensive analyses indicate that adverse events are common among medical cannabis users, with prevalence rates of approximately 26% overall and psychiatric adverse events occurring in 13.5% of patients. However, serious adverse events, treatment discontinuation due to side effects, and dependence typically affect fewer than 1 in 20 patients. Notably, studies with longer follow-up periods (≥24 weeks) report higher rates of adverse events, suggesting potential cumulative effects with extended use.

The adverse event profile varies significantly across different patient populations and formulations. In older adults (average age 66-73 years), the most frequently reported side effects include dry mouth (3.2-12.8%), drowsiness (8.6%), dizziness (2.2-4.0%), and somnolence (2.2%). Large observational studies demonstrate that serious adverse events are rare in this population, with no SAEs reported in multiple cohort studies spanning six months. However, French addictovigilance data from recreational use shows more concerning patterns, with psychiatric effects (51.2%), neurological effects (15.6%), and cardiac effects (7.8%) being prominent, along with emerging recognition of cannabinoid hyperemesis syndrome (2.8% of cases) and rare but documented fatalities.

Current evidence reveals significant gaps in high-quality safety data, particularly for higher-THC formulations and long-term use. Most clinical studies have evaluated THC concentrations below those currently available for prescription in some jurisdictions, with no safety data available for products containing THC concentrations above 22% w/w. Cannabis is contraindicated in patients with significant psychiatric, cardiovascular, renal, or hepatic illness, and important drug interactions exist, particularly CBD-mediated inhibition of clobazam metabolism. The limited pharmacokinetic and pharmacodynamic information necessitates a "start low and go slow" approach with careful monitoring, especially in vulnerable populations such as older patients who face increased risk of adverse effects.

Cannabis Rescheduling: Paving the Way for Pharma Innovation

The U.S. Department of Justice and DEA's decision to reschedule FDA-approved cannabis drug products and state-licensed medical cannabis from Schedule I to Schedule III marks a profound moment for the pharmaceutical industry. Effective April 2026, this regulatory adjustment is poised to dismantle significant barriers that have historically stifled rigorous clinical research and the development of evidence-based cannabis medicines. For decades, the Schedule I classification, which deemed cannabis as having no accepted medical use and high abuse potential, severely constrained scientific inquiry, making it difficult to conduct trials and secure necessary research materials.

This reclassification is not a federal legalization of cannabis, nor does it endorse the vast, unregulated consumer market. Instead, it creates a more conducive environment for legitimate pharmaceutical innovation. Companies with established infrastructure, like MediPharm Labs, which already possesses FDA site registration and a track record of supplying pharmaceutical-grade cannabis for clinical trials, are strategically positioned to capitalize on this shift. The move is expected to:

• Accelerate R&D: By easing research restrictions, the pathway for developing and bringing new FDA-approved cannabis-derived therapies to market will be significantly streamlined.

• Improve Financial Landscape: Relief from Internal Revenue Code §280E will alleviate substantial tax burdens, fostering greater investment and capital flow into the compliant pharmaceutical cannabis sector.

• Enhance Competitive Edge: Companies adhering to stringent pharmaceutical standards will gain a distinct advantage, differentiating their rigorously tested and approved products from the often-unregulated offerings.

However, the path forward is not without its complexities. While the rescheduling addresses a critical federal hurdle, it does not resolve the inherent conflicts between federal and state cannabis laws, nor does it authorize interstate commerce for non-FDA approved products. This continued regulatory ambiguity could still present operational challenges. Furthermore, the existence of a largely unregulated market for non-pharmaceutical cannabis products raises ongoing public health concerns regarding product safety, inconsistent quality, and potential harms, which could inadvertently affect the perception of all cannabis-related products. The potential for market consolidation also warrants attention, as the benefits of this shift may disproportionately favor larger, well-resourced entities, potentially overlooking equity considerations. Moving forward, a concerted effort to prioritize research access and public health surveillance will be crucial to ensure that this regulatory evolution truly serves patient needs and advances evidence-based medicine.